ORYN Stock Chart & Stats
$48.59
$0.00(0.00%)
At close: 4:00 PM EDT
$48.59
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$48.59 - $52.96
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$4.19B
Enterprise Value$230.85M
Total Cash (Recent Filing)$22.12M
Total Debt (Recent Filing)$7.10M
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding84,332,150
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.12
Revenue Forecast (FY)$189.33M
Bulls Say, Bears Say
Bulls Say
Proprietary Epigenetics FocusOryzon’s proprietary epigenetic approach gives it a defined scientific platform aimed at oncology and CNS disorders with high unmet need. If clinical development succeeds, this focused technology base could support multiple therapies and create durable differentiation beyond a single candidate.
Modest LeverageLow leverage provides greater financial flexibility than a heavily indebted development-stage biotech. With relatively limited debt obligations, Oryzon may have more capacity to fund research, manage clinical development volatility, and pursue strategic options without excessive refinancing pressure.
Growing Equity BaseMeaningful growth in total assets and equity strengthens the company’s financial foundation while its pipeline remains in development. A larger equity base can provide additional capacity to sustain research programs and absorb the long timelines inherent in clinical-stage biotechnology.
Bears Say
Persistent UnprofitabilityOryzon has not yet demonstrated a profitable operating model, as recurring operating and net losses continue to exceed any gross profit generated. This keeps the company dependent on external capital or future commercialization success to support its long-term development strategy.
Volatile Revenue BaseRepeated periods of zero revenue indicate that Oryzon lacks a stable commercial revenue base and remains reliant on irregular or non-recurring sources. This volatility makes financial planning less predictable and leaves future funding needs closely tied to pipeline progress and potential partnerships.
Ongoing Cash BurnPersistent negative operating and free cash flow shows that the business does not yet fund its own operations or development activities. Continued cash burn can require additional financing over time, potentially increasing dilution or limiting the pace and breadth of clinical investment.
Oryzon Genomics SA News
ORYN FAQ
What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest stock price was $48.59 and its highest was $52.96 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is $4.19B.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s upcoming earnings report date is Mar 04, 2027 which is in 123 days.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on Jul 27, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$1.179 by $1.179.
Is Oryzon Genomics SA overvalued?
According to Wall Street analysts Oryzon Genomics SA’s price is currently Overvalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA does not currently pay dividends.
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 84,332,150 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of $0 in its last earnings report, beating expectations of -$1.179. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in MX:ORYN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.